Chagas disease in Switzerland: Managing an emerging infection and interrupting its transmission;Maladie de Chagas en Suisse: Faire face à une maladie émergente et interrompre la chaîne de transmission

Revue Medicale Suisse

Volumn 4, Issue 157, 2008, Pages 1212-1217

  Jackson, Yves ^a,b   Chappuis, François ^a   Loutan, Louis ^a  

^a HUG   (Switzerland)

^b HUG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BENZNIDAZOLE; NIFURTIMOX;

CHAGAS DISEASE; DISEASE TRANSMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PROGNOSIS; REVIEW; RISK FACTOR; SOUTH AND CENTRAL AMERICA; SWITZERLAND;

ALGORITHMS; ANIMALS; CHAGAS DISEASE; COMMUNICABLE DISEASES, EMERGING; HUMANS; MASS SCREENING; RISK FACTORS; SWITZERLAND;

EID: 47149117383     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. ** Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis 2001;1:92-100.
2. * Barrett M, Burchmore R, Stich A, et al. The trypanosomiases. Lancet 2003;362:1469-80.
3. ** Bern C, Montgmery S, Herwaldt B, et al. Evaluation and treatment of Chagas disease in the United States - a systematic review. JAMA 2007;298:2171-81.
4. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcome of treating chronic Chagas disease with benznidazole versus no treatment. Ann Int Med 2006; 144:724-34.
5. Reyes P,Vallejo M. Trypanocidal drugs for late stage, symptomatic Chagas disease. Cochrane Database Syst Rev 2005;CD004102.
6. Villar J, Villar L, Min-Neto J, Ebrahuim S, Yusuf S. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst Rev 2002; CD003463.
7. Torrico F, Alonso-Vega C, Suarez E, et al. Maternal Trypanosoma cruzi infection, pregnancy outcome, morbidity, and mortality of congenitally infected and non-infected newborns in Bolivia. Am J Trop Med Hyg 2004;70:201-9.
8. Castro J, de Mecca M, Bartel L. Toxic side effects of drugs used to treat Chagas disease (American trypanosomiasis). Hum Exp Tox 2006;25:471-9.
9. Schijman A, Altcheh J, Burgos J, et al. Aetiological treatment of congenital Chagas disease diagnosed and monitored by the polymerase chain reaction. J Antimicrob Chemother 2003;52:441-9.
10. Andrade A, Martelli C, Oliveira R, et al. Benznidazole efficacy among Trypanosoma cruzi-infected adolescents after a six-year follow-up. Am J Trop Med Hyg 2004; 71:594-7.
11. Sartori A, Ibrahim K, Nunes Westphalen E, et al. Manifestations of Chagas disease (American trypanosomiasis) in patients with HIV/AIDS. Ann Trop Med Parasitol 2007;101:31-50.
12. CDC. Chagas disease after organ transplantation-Los Angeles, California 2006. MMWR 2006;55:798-800.
13. Diez M, Favaloro L, Bertolotti A, et al. Usefulness of PCR strategies for early diagnosis of Chagas disease reactivation and treatment follow-up in heart transplantation. Am J Transplant 2007;7:1633-40.
14. de Carvalho V, Sousa E, Vila J, et al. Heart transplantation in Chagas disease. 10 years after the initial experience. Circulation 1997;94:1815-7.
15. CDC. Blood donor screening for Chagas disease-United States 2006-2007. MMWR 2007;56:141-3.
16. Young C, Losikoff P, Chawla A, Glasser L, Forman E. Transfusion-acquired Trypanosoma cruzi infection. Transfusion 2007;47:540-4.
17. Barcán L, Luna C, Clara L, et al. Transmission of T cruzi infection via liver transplantation to a non reactive recipient for Chagas' disease. Liver Transpl 2005;11: 1112-6.